Summary.-Radiation survival curves for Lewis lung tumours in the lungs ranging in size from 0-5 to 20 mm3 have been obtained, and a size-dependent variation in hypoxic fraction was found. Cell-survival studies following treatment of various sizes of s.c. tumours indicated that the effects of 60Co y-rays and the chemotherapeutic agents 1,3-bas(2-chloroethyl)-1-nitrosourea (BCNU) and cyclophosphamide are all size-dependent. Large pulmonary nodules which had regressed but had not been cured by cyclophosphamide regrew with a radiosensitivity that was characteristic of previously untreated tumours. The results give additional experimental support to the clinical interest in early adjuvant therapy of micrometastases, and sequential combined modality therapy for larger tumours.
THE relationship between tumour size and therapeutic sensitivity has been the subject of a number of studies. Experiments from this laboratory have indicated that cells in 0-5-mm3 pulmonarv metastases of the Lewis lung (LL) tumour are considerably more radiosensitive under normal in situ conditions than those in 500-mm3 subcutaneous tumours (Shipley, Stanley and Steel, 1975) . At the level of cell survival studied, the presence of a hypoxic fraction could not be detected in 0-5-MM3 pulmonary tumours, whereas the hypoxic fraction in large s.c. tumours was estimated to be 0-36. Fu, Phillips and Wharam (1976) , working with the EMT6 tumour system, have also compared the radiosensitivity of large s.c. tumours with that of pulmonary nodules, and have found the smaller tumours to be considerably more radiosensitive and their hvpoxic fraction to be correspondingly lower. DeWys (1972) and Steel and Adams (1975) have found independently, in cell-survival studies with the LL tumour, that small pulmonary nodules are more sensitive to cyclophosphamide than are large s.c. tumours. Twentyman and Bleehen (1976) saw no size-dependent effect when the EMT6 tumour was treated with cyclophosphamide, although their data for the same tumour indicated that sensitivity to BCNU decreased with increasing tumour size.
Any effect of tumour size on therapeutic response has important clinical implications for the use both of prophylactic cytotoxic therapy against subclinical disease and of combined modality treatment of larger tumours. The project described in this report was designed to study in greater detail the response of the LL tumour to radiation and drug treatment over a range of sizes, and to investigate the radiosensitivity of regrowing lung nodules which had been treated initially with cyclophosphamide.
MATERIALS AND METHODS
Tumour system.-The Lewis lung (LL) tumour, which arose spontaneously in a C57BL mouse in 1951 (Sugiura and Stock, 1955) , was used throughout this study. I thas been serially transplanted through many generations of female C57BL mice of the Institute of Cancer Research colony by the s.c. injection into the flank of 10 5-106 viable tumour cells.
In the series of experiments reported here, tumours were either grown in the lung (from i.v. injections of tumour cells), or s.c. in the flank (from an injection of a suspension of single tumour cells), or on the surface of the dorsal muscle of the spine (by s.c. injection of a tumour homogenate). The pulmonary tumours were produced by injection into the tail vein of 0-2-ml aliquots of cell suspension each containing 104 viable tumour cells and 106 plastic microspheres (15 ,um diameter; 3M Company, Minneapolis, Minnesota). The technique was originally employed in the lung colony assay developed for this tumour (Hill and Stanley, 1975a ) and yielded in each animal an average of 20 lung colonies which were clearly visible after 10 days growth. By allowing different periods of time to elapse between implantation and experiment, it was possible to vary the size of nodule available for study.
This method of generating lung tumours was also used in experiments which investigated the ability of cyclophosphamide to cure mice bearing a number of pulmonary nodules. As these were long-term experiments, it was necessary to prevent the phenomenon of "tail-trapping" of tumour cells described by van den Brenk et al. (1975) . Consequently the tails of these animals were irradiated with 60Co y-rays to a dose of 3000 rad 4 days after i.v. injection to sterilize any residual cells.
Tumour homogenate suitable for s.c. implantation was obtained by passing tumour tissue fragments mixed with Eagle's basal medium (Gibco-Biocult Laboratories Ltd, Paisley) through a fine stainless steel mesh, and then through needles of successively narrower gauge until the suspension would pass freely through a 25-gauge needle. The homogenate was then diluted to 5 ml for each gram of tissue used. Aliquots of 0-01-0 04 ml, when injected between the skin and dorsal muscle of the spine of recipient mice, produced solid tumours ranging in volume from 2 to 100 mm3 8 days after implantation. Thus the response of a range of differently sized tumours to a chosen treatment could be measured on the same day.
Irradiation.-The irradiation of tumours in situ was given as a whole-body dose to unanaesthetized mice confined in perforated perspex containers. The dose rate of 60Co yrays was 300-350 rad/min at 30 cm skin-tosource distance. The mice were rotated through 1800 halfway through the irradiation, to give two equally weighted parallel-opposed fields. For irradiation under hypoxic conditions, mice were killed by asphyxiation with N2 15 min before treatment. Tumours were assayed immediately after both types of irradiation treatment. Cell-suspension technique and cell-survival assay.-Single-cell suspensions of treated and control tumours were prepared by trypsin digestion as previously described, with volumes of reagents scaled down proportionately when pulmonary tumours were used (Hill and Stanley, 1975a) .
The technique employed to assay the colony-forming ability in agar of the tumour cells surviving treatment was developed for the LL tumour by Courtenay (1976) Fig. 2 indicate considerable size-dependence at both sites; the surviving fraction of cells from 1-mm3 tumours treated with 1000 rad was approximately 0-001, and this value increased with size, giving 0-1 as the survival of 500-mm3 s.c. tumours after the same dose of radiation. In the overlapping region of the size ranges no difference in sensitivity between the two sites was detected.
Radiation dose-response curves for 20-mm3 and 6-mm3 pulmonary nodules treated in air-breathing mice are shown in Figs. 3a and 3b. Both sets of data appear to indicate increased radioresistance at high doses of radiation. This is consistent with standard radiobiological models for mixed-population survival curves in which the radiation response at high doses is determined by hypoxic cells. The lines drawn through both sets of points are those predicted theoretically by the multitarget single-hit survival-curve model for a mixed population of oxic and hypoxic cells (Elkind and Whitmore, 1967 estimated by measuring the diameter of 20-80 colonies on the lung surface with the aid of a dissecting microscope fitted with a calibrated eyepiece graticule. The values derived from these measurements were plotted against time and are shown in Fig. 4 as the control group. The error bars shown in Fig. 4 are the quartile values derived from the range of sizes observed at each interval. Analysis of these data has already been presented, and theoretical consideration of the growth curve of lung nodules in the microscopic phase (volume <0'1 mm3) has already been described (Steel, Adams and Stanley, 1976) . Earlier investigations in this laboratory indicated that, in the size range of lung nodules studied, the median intermitotic time for LL tumour cells was about 11-12 h, and growth fraction was in the range 55-70% (Hill and Stanley, 1977) . Little inter-experiment variation of growth rate has been observed throughout the course of the present experiments.
Previous results have shown that all mice treated with 300 mg/kg cyclophosphamide within 10-11 days of tumour cell injection were free of pulmonary disease 60 days later (Hill and Stanley, 1977) . If more than 11 days elapsed, a decline in cure rate was observed, which resulted in no 60-day survivors if treatment was delayed until 19-20 days after implantation. The approximate size of colonies which can be cured by cyclophosphamide is therefore 0-6 mm3, the median colony volume at Day 11, although the maximum size of tumour curable by 300 mg/kg cyclophosphamide is more likely to be represented by the upper limit of the tumour size distribution at this time point.
Mice bearing pulmonary tumours that had been growing for 16 days before cyclophosphamide treatment were rarely cured. The nodules underwent regression and regrowth, reaching the nadir at 10-11 days after treatment, at which time median colony volume had fallen from 6 mm3 to less than 1 mm3 (Fig. 4) by the agar colony assay. Pulmonary tumours which had regressed from 6 mm3 to less than 1 mm3 showed a radiosensitivity that was characteristic of untreated 0-5-mm3 nodules, with no evidence of a hypoxic "tail" observed in survival measurements down to 10-3 (Fig. 5) . Histological studies of the lungs removed during this experiment indicated that the great majority of cells in the tumour nodule were dead within 3 days of receiving the drug, and that growth foci were not visible until 10-12 days after treatment.
DISCUSSION
The influence of tumour size on therapeutic sensitivity is particularly relevant to recent clinical interest in prophylactic adjuvant chemotherapy for occult metastatic disease. Results indicate that this approach to treatment is producing a significant increase in tumour-free survival in patients treated for osteogenic sarcoma, carcinoma of the breast and rhabdomyosarcoma, diseases which have a high probability of early metastasis (Jaffe et al., 1974; Bonadonna et al., 1976; Heyn et al., 1974) . It is important to know the extent to which cure of metastatic disease by chemotherapy is limited by the size of the deposits and, if this size is exceeded, whether maximum sensitivity is regained after the regression produced by an initial treatment.
The present studies on the LL tumour indicate that cells in large tumours are less sensitive both to radiation and to cytotoxic drugs than cells in small nodules. At the doses of each agent that we have used, the level of cell kill measured in (Shipley et al., 1975) . S.c. and pulmonary tumours of the same size appear to be equally radiosensitive (Fig. 2) for both cyclophosphamide and BCNU, whereas the greatest change in sensitivity to radiation appears to take place in pulmonary tumours between 1 and 20 mm3 (Fig. 2) . While the emergence of a measurable hypoxic fraction in tumours greater than 5 mm3 explains the radiation results, the reason for size-dependence of response after drug treatment is not clear. Furthermore, unlike radiation treatment, BCNU appears to be more effective against pulmonary tumours than s.c. tumours of the same size (Fig. I a) . A number of studies have evaluated the response of various experimental tumour systems to this drug. Hagemann, Schenken and Lesher (1973) have studied the response of P815 x 2 mastocytoma cells grown in culture, ascites and solid forms. They found that solid tumours were far less 8 sensitive to the drug than either of the other forms and suggested that this was a consequence of the failure of the drug to reach significant numbers of cells at risk. Rosenblum et al. (1975) have studied the effect of BCNU on a rat brain tumour and found that the dose-response curve for this drug was biphasic, withl little extra cell kill noted at doses greater than 0 75 times the LD1o. They also considered that accessibility of this drug to clonogenic tumour cells might be the limiting factor in its effectiveness.
Earlier results from this laboratory indicated that BCNU treatment of the murine tumour B 16 melanoma left a surviving population that was predominantly hypoxic (Hill and Stanley, 1975b) , suggesting that radiation and BCNU spare the same sub-population of clonogenic tumour cells. The implication of this is not necessarily that the hypoxic state of the cells is directly responsible for their resistance to BCNU, as the failure of the drug to reach these cells in adequate concentrations would have the same effect.
The radiation dose-response curves from 6-mm3 and 20-mm3 pulmonary tumours have been analysed by comparison with curves predicted by a multi-target singlehit model for a mixed oxic and hypoxic cell population (Elkind and XVhitmore, 1967) . For both tumour sizes studied, the experimental data fitted quite closely to the terminal region of the theoretical curve predicted by the model (Figs. 3a  and 31) ). Both sets of data show a gradual inflexion before the radioresistant terminal portion, and for 6-mm3 nodules, surviving fractions between 041 and 0 01 lie consistently above the line predicted by the two-component model. These data may be better interpreted in terms of the model proposed by Tannock (1972) , which allows for a distribution of radiosensitivities between that of maximally sensitive and that of maximally resistant cells.
A large single dose of cyclophosphamide produced only regression and some growth delay in 16-day pulmonary tumours (Fig. 4) , resuilts which are qualitatively similar to those reported by Ovejera, Johnson and Goldin (1975) for the same tumour system. However, we have shown that the pulmonary nodules regrowing after cyclophosphamide treatment appeared to be as radiosentisive as previously untreated tumours (Fig. 5) . This indicates that the effect of drug treatment on the tumour cells and stroma did not impair the ability of the surviving population to reoxygenate and proliferate. These observations may be of some clinical relevance in combined modality treatment of pulmonary disease, using chemotherapy to shrink tumour nodules and consequently to reduce the proportion of hypoxic cells present in the tumour. Suit and Maeda (1967) , in studies on the mammary carcinoma MDAH-MCa-4 in C3H mice, observed that high pressure 02 administered during radiation treatment was only modestly effective in reducing the tumour-control dose for 250-mm3 tumours, whereas the same treatment was much more effective against 0-6-mm3 nodules. It is possible that a similar difference in response to high pressure 02 may exist between 500-mm3 LL tumours with a 0-36 hypoxic fraction and 6-and 20-mm3 pulmonary tumours with hypoxic fractions of 0-01 and 0'05 respectively.
The principal finding of this study has been that, although pulmonary nodules less than 1 mm3 in volume are markedly more sensitive to cytotoxic therapy than larger tumours, this advantage rapidly decreases over 4-5 volume doublings in the case of radiation treatment, due to developing hypoxia. There appear to be critical size ranges over which cellular sensitivity to drugs and radiation changes. For radiation this takes place between 1 and 10 mm3, the size range over which necrosis first becomes visible, whereas the change in sensitivity to drug treatment occurs in the size range between 1 and 100 mm8. It is not known whether in man the critical size range may be similar; in radiographically demonstrable metastatic disease the size of the smallest pulmonary deposits is considerably larger than the most radiosensitive size reported here. The concept of a critical size range may have important implications both for prophylactic therapy of occult metastatic disease and for combined modality treatment of larger tumour deposits. If chemotherapy can shrink metastatic nodules through this size range, then a useful improvement may be gained in subsequent radiotherapy.
